Correlation Between Neurocrine Biosciences and Eyepoint Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Neurocrine Biosciences and Eyepoint Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurocrine Biosciences and Eyepoint Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neurocrine Biosciences and Eyepoint Pharmaceuticals, you can compare the effects of market volatilities on Neurocrine Biosciences and Eyepoint Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurocrine Biosciences with a short position of Eyepoint Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurocrine Biosciences and Eyepoint Pharmaceuticals.

Diversification Opportunities for Neurocrine Biosciences and Eyepoint Pharmaceuticals

0.16

Correlation Coefficient

Neurocrine Biosciences  Eyepoint Pharmaceuticals

Average diversification

The 3 months correlation between Neurocrine and Eyepoint is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Neurocrine Biosciences and Eyepoint Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eyepoint Pharmaceuticals and Neurocrine Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurocrine Biosciences are associated (or correlated) with Eyepoint Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eyepoint Pharmaceuticals has no effect on the direction of Neurocrine Biosciences i.e., Neurocrine Biosciences and Eyepoint Pharmaceuticals go up and down completely randomly.

Pair Corralation between Neurocrine Biosciences and Eyepoint Pharmaceuticals

Given the investment horizon of 90 days Neurocrine Biosciences is expected to generate 0.28 times more return on investment than Eyepoint Pharmaceuticals. However, Neurocrine Biosciences is 3.53 times less risky than Eyepoint Pharmaceuticals. It trades about 0.05 of its potential returns per unit of risk. Eyepoint Pharmaceuticals is currently generating about 0.0 per unit of risk. If you would invest  12,225  in Neurocrine Biosciences on September 13, 2024 and sell it today you would earn a total of  597.00  from holding Neurocrine Biosciences or generate 4.88% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Neurocrine Biosciences  vs.  Eyepoint Pharmaceuticals

Neurocrine Biosciences

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Neurocrine Biosciences are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong forward indicators, Neurocrine Biosciences is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Eyepoint Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eyepoint Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Eyepoint Pharmaceuticals is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Neurocrine Biosciences and Eyepoint Pharmaceuticals

The main advantage of trading using opposite Neurocrine Biosciences and Eyepoint Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurocrine Biosciences position performs unexpectedly, Eyepoint Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyepoint Pharmaceuticals will offset losses from the drop in Eyepoint Pharmaceuticals' long position.

The idea behind Neurocrine Biosciences and Eyepoint Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.